CN1178533A - 分离加兰他敏的方法 - Google Patents
分离加兰他敏的方法 Download PDFInfo
- Publication number
- CN1178533A CN1178533A CN96192578A CN96192578A CN1178533A CN 1178533 A CN1178533 A CN 1178533A CN 96192578 A CN96192578 A CN 96192578A CN 96192578 A CN96192578 A CN 96192578A CN 1178533 A CN1178533 A CN 1178533A
- Authority
- CN
- China
- Prior art keywords
- lycoremine
- treatment
- purposes
- liquid
- described method
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 title claims abstract description 114
- 229960003980 galantamine Drugs 0.000 title claims abstract description 58
- 238000000034 method Methods 0.000 title claims abstract description 34
- HPOIPOPJGBKXIR-UHFFFAOYSA-N 3,6-dimethoxy-10-methyl-galantham-1-ene Natural products O1C(C(=CC=2)OC)=C3C=2CN(C)CCC23C1CC(OC)C=C2 HPOIPOPJGBKXIR-UHFFFAOYSA-N 0.000 title claims abstract description 11
- LPCKPBWOSNVCEL-UHFFFAOYSA-N Chlidanthine Natural products O1C(C(=CC=2)O)=C3C=2CN(C)CCC23C1CC(OC)C=C2 LPCKPBWOSNVCEL-UHFFFAOYSA-N 0.000 title claims abstract description 11
- BGLNUNCBNALFOZ-WMLDXEAASA-N galanthamine Natural products COc1ccc2CCCC[C@@]34C=CCC[C@@H]3Oc1c24 BGLNUNCBNALFOZ-WMLDXEAASA-N 0.000 title claims abstract description 11
- ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 title claims abstract description 11
- IYVSXSLYJLAZAT-NOLJZWGESA-N lycoramine Natural products CN1CC[C@@]23CC[C@H](O)C[C@@H]2Oc4cccc(C1)c34 IYVSXSLYJLAZAT-NOLJZWGESA-N 0.000 title claims abstract description 11
- 208000024827 Alzheimer disease Diseases 0.000 claims abstract description 10
- 208000007848 Alcoholism Diseases 0.000 claims abstract description 9
- 201000002862 Angle-Closure Glaucoma Diseases 0.000 claims abstract description 9
- 206010057852 Nicotine dependence Diseases 0.000 claims abstract description 9
- 208000025569 Tobacco Use disease Diseases 0.000 claims abstract description 9
- 201000007930 alcohol dependence Diseases 0.000 claims abstract description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 23
- 238000000605 extraction Methods 0.000 claims description 11
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 10
- 239000012620 biological material Substances 0.000 claims description 9
- 241000234479 Narcissus Species 0.000 claims description 8
- 206010036631 Presenile dementia Diseases 0.000 claims description 8
- 239000007788 liquid Substances 0.000 claims description 8
- 238000000638 solvent extraction Methods 0.000 claims description 8
- 241000196324 Embryophyta Species 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 6
- 238000000622 liquid--liquid extraction Methods 0.000 claims description 6
- 239000002904 solvent Substances 0.000 claims description 6
- 238000009835 boiling Methods 0.000 claims description 5
- 235000017550 sodium carbonate Nutrition 0.000 claims description 5
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 5
- 241001532689 Narcissus pseudonarcissus Species 0.000 claims description 4
- 239000003960 organic solvent Substances 0.000 claims description 4
- 230000001225 therapeutic effect Effects 0.000 claims description 4
- 231100000027 toxicology Toxicity 0.000 claims description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 3
- 239000003518 caustics Substances 0.000 claims description 3
- 239000003885 eye ointment Substances 0.000 claims description 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 3
- 238000001953 recrystallisation Methods 0.000 claims description 3
- 240000003527 Crinum asiaticum Species 0.000 claims description 2
- 239000000284 extract Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 5
- 241000234270 Amaryllidaceae Species 0.000 claims 1
- 231100000252 nontoxic Toxicity 0.000 claims 1
- 230000003000 nontoxic effect Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229940124531 pharmaceutical excipient Drugs 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract description 7
- 229930013930 alkaloid Natural products 0.000 abstract description 7
- 150000003797 alkaloid derivatives Chemical class 0.000 abstract description 6
- 238000002360 preparation method Methods 0.000 abstract description 4
- 238000002955 isolation Methods 0.000 abstract 1
- 239000003513 alkali Substances 0.000 description 12
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 8
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 6
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 238000010298 pulverizing process Methods 0.000 description 4
- 235000015256 Chionanthus virginicus Nutrition 0.000 description 3
- 241000234271 Galanthus Species 0.000 description 3
- 244000223141 Leucojum aestivum Species 0.000 description 3
- 229910021529 ammonia Inorganic materials 0.000 description 3
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- PIJVFDBKTWXHHD-UHFFFAOYSA-N Physostigmine Natural products C12=CC(OC(=O)NC)=CC=C2N(C)C2C1(C)CCN2C PIJVFDBKTWXHHD-UHFFFAOYSA-N 0.000 description 2
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 2
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 239000000544 cholinesterase inhibitor Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 229960002362 neostigmine Drugs 0.000 description 2
- LULNWZDBKTWDGK-UHFFFAOYSA-M neostigmine bromide Chemical compound [Br-].CN(C)C(=O)OC1=CC=CC([N+](C)(C)C)=C1 LULNWZDBKTWDGK-UHFFFAOYSA-M 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 229960001697 physostigmine Drugs 0.000 description 2
- PIJVFDBKTWXHHD-HIFRSBDPSA-N physostigmine Chemical compound C12=CC(OC(=O)NC)=CC=C2N(C)[C@@H]2[C@@]1(C)CCN2C PIJVFDBKTWXHHD-HIFRSBDPSA-N 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Substances [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 235000015320 potassium carbonate Nutrition 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- GXFZCDMWGMFGFL-KKXMJGKMSA-N (+)-Tubocurarine chloride hydrochloride Chemical compound [Cl-].[Cl-].C([C@H]1[N+](C)(C)CCC=2C=C(C(=C(OC3=CC=C(C=C3)C[C@H]3C=4C=C(C(=CC=4CC[NH+]3C)OC)O3)C=21)O)OC)C1=CC=C(O)C3=C1 GXFZCDMWGMFGFL-KKXMJGKMSA-N 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 241001111317 Chondrodendron tomentosum Species 0.000 description 1
- 241001503987 Clematis vitalba Species 0.000 description 1
- 239000008709 Curare Substances 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000000474 Poliomyelitis Diseases 0.000 description 1
- 241000282941 Rangifer tarandus Species 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 239000003637 basic solution Substances 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 239000002329 esterase inhibitor Substances 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000479 mixture part Substances 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000012261 resinous substance Substances 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 235000011121 sodium hydroxide Nutrition 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/06—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
Abstract
本发明的目标是分离生物碱加兰他敏(结构式Ⅰ)的方法,由所述方法生成的加兰他敏,由此生成的植物制剂形式的加兰他敏的用途,以及由此生成的加兰他敏在治疗闭角型青光眼、早老性痴呆(Alzheimer’s disease)和酒精及尼古丁依赖性方面的用途。
Description
本发明涉及分离生物碱加兰他敏的方法；由该方法生成的加兰他敏；由此制成的植物制剂(盖仑制剂)形式的加兰他敏的用途；以及由此生成的加兰他敏在治疗闭角型青光眼、早老性痴呆(Alzheimer’s disease)和酒精及尼古丁依赖性方面的用途。
加兰他敏(4a，5，9，10，11，12-六氢-3-甲氧基-11-甲基-6H-苯并呋喃并(3a，3，2-ef)-(2)并氮杂-6-醇)是一种四环生物碱，因其药理特性而属于具可逆作用的胆碱酯酶抑制剂。其作用类似于毒扁豆碱和新斯的明。但是，它还具有其独有的特性，例如可与吗啡相比的强镇痛作用。作为胆碱酯酶抑制剂，加兰他敏的治疗范围比毒扁豆碱和新斯的明宽3至6倍，因为它并不象它们那样有毒。该优点弥补了相对于剂量其胆碱酯酶抑制作用稍低的不足。加兰他敏被用于治疗脊髓灰质炎和各种神经系统疾病，但主要用于治疗闭角型青光眼和作为使用箭毒后的解毒药。使用加兰他敏治疗早老性痴呆尚在试验阶段。最近，还记述了将其用于治疗酒精及尼古丁依赖性(DE-OS4010079，DE-OS4301782)。
早老性痴呆、酒精及尼古丁依赖性以及闭角型青光眼的治疗需要适应具体情况的长效药物剂型。这可以是用于治疗闭角型青光眼的眼膏。在早老性痴呆和酒精或尼古丁依赖性的治疗中，显然，复杂治疗方案或长时间输注是不适当的。在这些疾病中，透皮治疗系统(TTS)是一种适宜的形式，例如DE-OS4301783中所述的。完整的皮肤或角膜都不能吸收活性成份的盐。因此，在治疗闭角型青光眼、早老性痴呆、或酒精及尼古丁依赖性时不能在软膏或TTS中使用氢溴酸加兰他敏或盐酸加兰他敏。所以，必须使用纯加兰他敏碱。
由于其具有有三个光学活性碳原子的复杂的四环结构，所以不可能经济有效地合成加兰他敏碱。因此，通常从石蒜科植物，例如雪花莲属，诸如snowdrop或夏雪片莲(Leucojum aestivum)中分离加兰他敏。这些植物的优点在于含有浓度高达0.3％的加兰他敏和少量的相伴生物碱，因此可使用DE-PS1193061中所述的萃取方法。但是，雪花莲属和夏雪片莲都是受保护的。另一方面，DE-PS1193061中所述的萃取方法最好使用含氯烃，但后者因其毒性而受到限制。因此，西方的药典提出含氯烃的残留量必须小于10ppm。所以，在药物的制备中应尽可能避免使用含氯烃。而且，在已知的方法中，必须由氧化铝吸附溶剂萃取液以确保树脂状物质与相伴生物碱分离。然后，从滤除了氧化铝的溶液中通过氢溴酸加兰他敏纯化加兰他敏；这就涉及到卤素盐的处理。为了用于软膏或TTS，然后必须从氢溴酸加兰他敏中游离出加兰他敏碱。
所以，本发明的目的之一是提供一种没有现有技术的缺点的分离和纯化加兰他敏的方法。具体地说，该方法方便了纯化，避免了使用含氯烃和利用加兰他敏盐进行的纯化。该目的是通过本发明中特征如权利要求1所述的方法达到的。从属权利要求对优选实施方式的特征进行了描述。
具体地说，本发明的主体是从生物材料中分离加兰他敏的方法，生物材料收获自农业栽培的石蒜科植物或那些通常被认作“杂草”的非保护植物，最好是自这些植物的球茎分离。这些石蒜科植物包括例如水仙或文殊兰(cimum)。尤其适合的是黄水仙(Narcissus paseudonarcissus，“Carlton”)或苏门答腊文殊兰(Asian climber，Crinum amabile)。虽然这些植物中加兰他敏含量只有受保护植物的十分之一，而且具有多达12种的相伴生物碱，但令人惊奇的是本发明的方法能够从中分离出药用纯度的加兰他敏碱。
根据本发明，用毒理学上安全的有机溶剂萃取含有加兰他敏的生物材料，并利用液-液萃取从萃取液中提纯加兰他敏，最好将原料粉碎并与碱性粉末混合，碱粉末最好是氢氧化钠颗粒、碳酸钠、碳酸钾、或其它适合从生物材料中游离出碱并制备成药理活性物质的类似的盐。对成功实施本发明方法来说尤其重要的是在液-液萃取的第一阶段维持pH值。液-液萃取第一阶段的pH约为4，第二阶段约为9。除了浓氨之外，还可以使用其它碱的碳酸钠溶液来调节pH值。利用乙醚或特定沸点汽油作为毒理学上安全的有机溶剂。以使用特别沸点的汽油为佳，利用它可以达到一定程度的预纯化。将溶剂去除；从合适的溶剂，最好是异丙醇中重结晶加兰他敏。由此可获得熔点为129至130℃的白色加兰他敏碱。由此获得的加兰他敏的纯度显示在HPLC色谱(图2)中。
该结果是令人震惊的，因为使用至今的DE-PS1193061所述的方法被发现是不适用于从含有少量加兰他敏而且含有多达12种相伴生物碱的生物材料中分离加兰他敏的。DE-PS1193061所述的方法会形成难以破乳的乳状液，使得萃取无法进行。略加改进后的该方法生成油状残留物，根据HPLC色谱(图1)所示，至少被4种物质所污染。
所以，必须将此认为是一项惊人的特殊发现，即无需另外的氧化铝吸附步骤，利用本发明的简单方法可从除大量相伴生物碱之外含有少量加兰他敏的生物材料中高产率地分离出纯的游离加兰他敏碱。
由本发明方法制备的加兰他敏碱可用于治疗闭角型青光眼、早老性痴呆或酒精及尼古丁依赖性。此外，本发明方法制备的加兰他敏碱还可用于同样可治疗上述疾病的植物制剂，例如眼膏或透皮治疗系统。
以下实施例更具体地说明了本发明，它们只用于说明本发明而并不限定本发明。实施例1(比较实施例)：
根据DE-PS1193061所述的方法，小心地将10kg晾干并粉碎的黄水仙(Narcissus pseudonarcissus，“Carlton”)球茎与2.5L 8％的氨水溶液混合。原料发生溶胀；整批原料成为膏状。为了萃取而加入23L二氯乙烷，结果生成无法破乳的乳状液。
实施例2(比较实施例)：
对本领域已知的分离加兰他敏的方法(DE-PS1193061)进行改良。小心地将10kg晾干并粉碎的黄水仙(Narcissus pseudonarcissus，“Carlton”)球茎与400g碳酸钠混合。加入23L二氯乙烷。将混合物静置10小时；然后倾去溶剂。再一次用23L二氯乙烷浸泡球茎，2至3小时后倾去溶剂。然后，在球茎中第三次加入17L二氯乙烷；但是，这次立即倾去溶剂。用10％的硫酸(2×600ml；2×300ml)萃取混合后的二氯乙烷萃取液。混合酸萃取液，加入乙醚振荡以去除微量二氯乙烷进行纯化。边搅拌边冷却至15至20℃，然后加入25％的氨水溶液约200ml，直至石蕊反应呈碱性。pH范围为7至8。与现有技术中所说的不同，相伴生物碱没有沉淀。用盐使碱性溶液饱和并用乙醚萃取。蒸发去除乙醚后，留下微量残留物，这也与现有技术中所说的不同。用碳酸钾使水相饱和，将其pH调节至约14。用乙醚重复萃取水相。将混合后的乙醚萃取液蒸干，将留下的含加兰他敏的残留物溶解在丙酮(50ml)中。与现有技术相反，其中没有沉淀。再加入350ml丙酮，加入200g氧化铝，搅拌45分钟。滤出氧化铝，各用100ml丙酮洗涤两次。将合并后的丙酮溶液蒸干，获得1.3g油状残留物，用HPLC进行检测。其色谱如图1所述。对主峰，即加兰他敏作了标明。显然，由此获得的加兰他敏至少被4种物质所污染。
实施例3
小心地将100kg晾干的并经粉碎的黄水仙(Narcissus pseudonarcissus，“Carlton”)球茎与4kg碳酸钠混合。将混合物分成3等份，每份用15L特定沸点汽油80/110浸渍。将混合物静置24小时。分别更换两次溶剂，收集溶剂，在真空下蒸发至干。将萃取液加入2％硫酸水溶液，用浓氨水溶液调节pH至4。然后用乙醚萃取5次。用浓氨水将水相的pH调节至9，用乙醚萃取5次。汇集各份醚萃取液后用硫酸钠干燥，然后蒸发。由此获得20g浅黄色油状残留物，然后在热异丙醇中重结晶。由此获得10g熔点为129至130℃的白色加兰他敏碱。在HPLC色谱(图2)中只看见一个峰。
Claims (24)
1.一种分离加兰他敏的方法，其特征在于，用毒理学上安全的有机溶剂来萃取含加兰他敏的生物材料，利用液-液萃取来纯化萃取液中的加兰他敏，所述的液-液萃取其第一阶段约在pH4进行。
2.根据权利要求1所述的方法，其特征在于，在萃取前生物材料被粉碎并与碱粉末混合。
3.根据权利要求1或2所述的方法，其特征在于，液-液萃取的第二阶段约在pH9进行。
4.根据权利要求1至3中任一项所述的方法，其特征在于，使用碳酸钠作为碱粉末。
5.根据权利要求1至4中任一项所述的方法，其特征在于，使用乙醚或特定沸点汽油作为毒理学上无毒的有机溶剂，优选特定沸点汽油。
6.根据权利要求1至5中任一项所述的方法，其特征在于，在合适的溶剂中重结晶以上制得的加兰他敏。
7.根据权利要求6所述的方法，其特征在于，使用异丙醇作为溶剂。
8.根据权利要求1至7中任一项所述的方法，其特征在于，使用植物的某部分，最好是石蒜科的球茎作为生物材料。
9.根据权利要求1至8中任一项所述的方法，其特征在于，使用的石蒜科植物是水仙，最好是黄水仙(Narcissus pseudonarcissus，“Carlton”)，或文殊兰，最好是苏门答腊文殊兰(Crinum amabile)。
10.根据权利要求1至9中任一项所述方法生成的加兰他敏。
11.根据权利要求10所述的加兰他敏在植物制剂(盖仑制剂中)的用途。
12.根据权利要求10所述的加兰他敏在眼膏中的用途。
13.根据权利要求10所述的加兰他敏在透皮治疗系统中的用途。
14.根据权利要求10所述的加兰他敏在治疗闭角型青光眼中的用途。
15.根据权利要求10所述的加兰他敏在治疗早老性痴呆中的用途。
16.根据权利要求10所述的加兰他敏在治疗酒精依赖性中的用途。
17.根据权利要求10所述的加兰他敏在治疗尼古丁依赖性中的用途。
18.一种药物制剂，其特征在于，除了至今已知的药用辅料外还包含权利要求10所述的加兰他敏。
19.根据权利要求18所述的供外用的药物产品。
20.根据权利要求18或19所述的用于治疗闭角型青光眼的药物产品。
21.根据权利要求18或19所述的用于治疗早老性痴呆的药物产品。
22.根据权利要求18或19所述的用于治疗酒精依赖性的药物产品。
23.根据权利要求18或19所述的用于治疗尼古丁依赖性的药物产品。
24.用于人的治疗方法，其特征在于，使用权利要求10所述的加兰他敏或权利要求18或19中任一项所述的药物制剂。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19509663.0 | 1995-03-17 | ||
| DE19509663A DE19509663A1 (de) | 1995-03-17 | 1995-03-17 | Verfahren zur Isolierung von Galanthamin |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1178533A true CN1178533A (zh) | 1998-04-08 |
| CN1088460C CN1088460C (zh) | 2002-07-31 |
Family
ID=7756925
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN96192578A Expired - Lifetime CN1088460C (zh) | 1995-03-17 | 1996-03-14 | 分离加兰他敏的方法 |
Country Status (23)
| Country | Link |
|---|---|
| US (5) | US5877172A (zh) |
| EP (2) | EP0815112B1 (zh) |
| JP (1) | JP3863180B2 (zh) |
| KR (1) | KR100427093B1 (zh) |
| CN (1) | CN1088460C (zh) |
| AT (2) | ATE247473T1 (zh) |
| AU (1) | AU707203B2 (zh) |
| CA (1) | CA2215351C (zh) |
| CZ (1) | CZ294722B6 (zh) |
| DE (3) | DE19509663A1 (zh) |
| DK (2) | DK0815112T3 (zh) |
| ES (2) | ES2162035T3 (zh) |
| HU (1) | HU225267B1 (zh) |
| IL (1) | IL117371A (zh) |
| MY (1) | MY114698A (zh) |
| NO (1) | NO316380B1 (zh) |
| NZ (1) | NZ304008A (zh) |
| PL (1) | PL184238B1 (zh) |
| PT (2) | PT815112E (zh) |
| SI (1) | SI1095656T1 (zh) |
| SK (1) | SK283861B6 (zh) |
| WO (1) | WO1996029332A1 (zh) |
| ZA (1) | ZA962140B (zh) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100400043C (zh) * | 2001-04-24 | 2008-07-09 | Hf医药研究有限公司 | 加兰他敏在制备治疗精神物质所致中枢神经系统病症药物中的应用 |
| CN101080231B (zh) * | 2004-12-17 | 2010-11-17 | 因德纳有限公司 | 氢溴酸加兰他敏的制备方法 |
| CN102050826A (zh) * | 2010-12-21 | 2011-05-11 | 浙江工业大学 | 一种分离加兰他敏的方法 |
| CN101787028B (zh) * | 2010-01-12 | 2012-01-04 | 恩施清江生物工程有限公司 | 一种从忽地笑中提取加兰他敏的方法 |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19509663A1 (de) * | 1995-03-17 | 1996-09-19 | Lohmann Therapie Syst Lts | Verfahren zur Isolierung von Galanthamin |
| AT402691B (de) * | 1996-01-26 | 1997-07-25 | Sanochemia Ltd | Verwendung von galanthamin zum herstellen von arzneimitteln zur behandlung von trisomie 21 oder verwandter trisomie-syndrome |
| EP1150695B1 (en) * | 1999-01-11 | 2007-02-28 | Atanas Russinov Djananov | Herbal supplement for increased muscle strength and endurance for athletes |
| US8603546B2 (en) * | 1999-01-11 | 2013-12-10 | Herbaceuticals Inc. | Herbal supplement for increased muscle strength and endurance for athletes |
| DE19906975B4 (de) * | 1999-02-19 | 2004-04-15 | Lts Lohmann Therapie-Systeme Ag | Arzneiform zur Behandlung von Alzheimer'scher Demenz |
| DE19906974C2 (de) * | 1999-02-19 | 2003-10-09 | Lohmann Therapie Syst Lts | Verwendung von Desoxypeganin zur Behandlung des Alkoholismus |
| GB9909469D0 (en) * | 1999-04-23 | 1999-06-23 | Wilkinson John A | Insectidal composition |
| US6426097B2 (en) * | 2000-01-28 | 2002-07-30 | Herbaceuticals Inc. | Herbal supplement for cognitive related impairment due to estrogen loss |
| CA2310926C (en) * | 2000-04-03 | 2002-10-15 | Janssen Pharmaceutica N.V. | A use of galantamine for the treatment of neuropsychiatric behaviour associated with alzheimer's disease |
| DE10129265A1 (de) * | 2001-06-18 | 2003-01-02 | Hf Arzneimittelforsch Gmbh | Wirkstoff-Kombination zur medikamentösen Sucht- oder Rauschmitteltherapie |
| DE10134038A1 (de) * | 2001-07-12 | 2003-02-06 | Hf Arzneimittelforsch Gmbh | Wirkstoff-Kombination zur medikamentösen Therapie der Nikotinabhängigkeit |
| EP1461611B1 (en) * | 2001-12-10 | 2010-03-03 | Washington University | Diagnostic for early stage alzheimer's disease |
| US20040067934A1 (en) * | 2002-10-03 | 2004-04-08 | Parys Wim Louis Julien | Use of galantamine for the treatment of neuropsychiatric behaviour associated with alzheimer's disease |
| CA2516618A1 (en) * | 2003-02-27 | 2004-09-10 | Shirankai Kyoto University Faculty Of Medicine Alumni Association Inc. | Pharmaceutical composition for treatment of drug dependence |
| US20050143350A1 (en) * | 2003-11-19 | 2005-06-30 | Seed John C. | Combination drug therapy to treat obesity |
| WO2005065662A1 (en) * | 2003-12-31 | 2005-07-21 | Actavis Group Hf | Solid dosage formulations of galantamine |
| CA2551946A1 (en) * | 2003-12-31 | 2005-07-21 | Actavis Group Hf | Immediate, controlled and sustained release formulations of galantamine |
| WO2006013546A2 (en) * | 2004-07-28 | 2006-02-09 | Ranbaxy Laboratories Limited | Process for the preparation of pure galantamine |
| FR2879599B1 (fr) * | 2004-12-16 | 2007-03-23 | Centre Nat Rech Scient Cnrse | Utilisation de la chromatographie de partage centrifuge pour la purification de la galanthamine |
| CN101142220A (zh) * | 2005-03-17 | 2008-03-12 | 伊瓦克斯制药有限公司 | 从生物材料分离加兰他敏 |
| PT1895994E (pt) * | 2005-05-13 | 2010-12-03 | Alza Corp | Sistema de administração de medicamentos de camada múltipla com barreira contra o fluxo de material do reservatório |
| CN1307180C (zh) * | 2005-05-24 | 2007-03-28 | 天津大学 | 从石蒜或雪花莲属原料中提取加兰他敏的方法 |
| EP1937226A2 (en) * | 2005-09-23 | 2008-07-02 | Alza Corporation | Transdermal galantamine delivery system |
| US7446352B2 (en) * | 2006-03-09 | 2008-11-04 | Tela Innovations, Inc. | Dynamic array architecture |
| JP2009084281A (ja) | 2007-09-18 | 2009-04-23 | Ethicon Endo Surgery Inc | 術後イレウスの低減のための方法 |
| CA2736982C (en) * | 2008-09-11 | 2019-01-15 | I.B.R. Israeli Biotechnology Research Ltd. | Leucojum bulb extracts and use thereof |
| US8247405B2 (en) * | 2008-12-10 | 2012-08-21 | Conopco, Inc. | Skin lightening compositions with acetylcholinesterase inhibitors |
| CN101602767B (zh) * | 2009-05-26 | 2012-01-11 | 苏州派腾生物医药科技有限公司 | 一种加兰他敏的制备方法 |
| DE102009040381A1 (de) | 2009-09-07 | 2011-03-17 | Kallimopoulos, Thomas, Dr. | Verfahren zur Isolierung von Alkaloiden aus Pflanzen |
| BG67337B1 (bg) | 2018-05-23 | 2021-06-15 | Софарма Ад | Метод за получаване на пречистен галантамин хидробромид |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1193061B (de) * | 1961-12-20 | 1965-05-20 | Vni Chimiko Pharmazewtitschesk | Verfahren zur Gewinnung von Galanthamin-hydrobromid aus Pflanzen der Familie der Amaryllidaceen |
| US4663318A (en) * | 1986-01-15 | 1987-05-05 | Bonnie Davis | Method of treating Alzheimer's disease |
| DE4010079A1 (de) * | 1990-03-29 | 1991-10-02 | Lohmann Therapie Syst Lts | Pharmazeutische formulierung zur behandlung des alkoholismus |
| US5519017A (en) * | 1990-03-29 | 1996-05-21 | Lts Lohmann Therapie-Systeme Gmbh + Co. Kg | Pharmaceutic formulation for the treatment of alcoholism |
| DE69229781T2 (de) * | 1991-05-14 | 2000-01-05 | Ernir Snorrason | Behandlung des ermüdungssyndroms mit cholinesteraseinhibitoren |
| US5336675A (en) * | 1991-05-14 | 1994-08-09 | Ernir Snorrason | Method of treating mania in humans |
| DE4301782C1 (de) * | 1993-01-23 | 1994-08-25 | Lohmann Therapie Syst Lts | Verwendung von Galanthamin zur Behandlung der Nicotinabhängigkeit |
| DE4301783C1 (de) * | 1993-01-23 | 1994-02-03 | Lohmann Therapie Syst Lts | Transdermales therapeutisches System mit Galanthamin als wirksamem Bestandteil |
| US5428159A (en) * | 1994-04-08 | 1995-06-27 | Ciba-Geigy Corporation | Method of manufacture of (-)-galanthamine in high yield and purity substantially free of epigalanthamine |
| DE19509663A1 (de) * | 1995-03-17 | 1996-09-19 | Lohmann Therapie Syst Lts | Verfahren zur Isolierung von Galanthamin |
-
1995
- 1995-03-17 DE DE19509663A patent/DE19509663A1/de active Pending
-
1996
- 1996-03-05 IL IL11737196A patent/IL117371A/xx not_active IP Right Cessation
- 1996-03-14 HU HU9802234A patent/HU225267B1/hu unknown
- 1996-03-14 AT AT01100944T patent/ATE247473T1/de active
- 1996-03-14 PT PT96907470T patent/PT815112E/pt unknown
- 1996-03-14 SK SK1235-97A patent/SK283861B6/sk not_active IP Right Cessation
- 1996-03-14 CA CA002215351A patent/CA2215351C/en not_active Expired - Lifetime
- 1996-03-14 AT AT96907470T patent/ATE203993T1/de active
- 1996-03-14 US US08/913,461 patent/US5877172A/en not_active Expired - Lifetime
- 1996-03-14 CZ CZ19972835A patent/CZ294722B6/cs not_active IP Right Cessation
- 1996-03-14 ES ES96907470T patent/ES2162035T3/es not_active Expired - Lifetime
- 1996-03-14 DE DE59610680T patent/DE59610680D1/de not_active Expired - Lifetime
- 1996-03-14 ES ES01100944T patent/ES2206356T3/es not_active Expired - Lifetime
- 1996-03-14 KR KR1019970706476A patent/KR100427093B1/ko not_active IP Right Cessation
- 1996-03-14 CN CN96192578A patent/CN1088460C/zh not_active Expired - Lifetime
- 1996-03-14 DK DK96907470T patent/DK0815112T3/da active
- 1996-03-14 AU AU51088/96A patent/AU707203B2/en not_active Expired
- 1996-03-14 EP EP96907470A patent/EP0815112B1/de not_active Expired - Lifetime
- 1996-03-14 SI SI9630641T patent/SI1095656T1/xx unknown
- 1996-03-14 EP EP01100944A patent/EP1095656B1/de not_active Expired - Lifetime
- 1996-03-14 NZ NZ304008A patent/NZ304008A/en not_active IP Right Cessation
- 1996-03-14 PT PT01100944T patent/PT1095656E/pt unknown
- 1996-03-14 WO PCT/EP1996/001094 patent/WO1996029332A1/de active IP Right Grant
- 1996-03-14 DE DE59607450T patent/DE59607450D1/de not_active Expired - Lifetime
- 1996-03-14 DK DK01100944T patent/DK1095656T3/da active
- 1996-03-14 PL PL96322463A patent/PL184238B1/pl unknown
- 1996-03-14 JP JP52805596A patent/JP3863180B2/ja not_active Expired - Lifetime
- 1996-03-15 ZA ZA962140A patent/ZA962140B/xx unknown
- 1996-03-15 MY MYPI96000954A patent/MY114698A/en unknown
-
1997
- 1997-09-08 NO NO19974119A patent/NO316380B1/no not_active IP Right Cessation
-
1998
- 1998-08-07 US US09/130,883 patent/US6194404B1/en not_active Expired - Lifetime
-
2000
- 2000-12-21 US US09/741,436 patent/US6335328B2/en not_active Expired - Lifetime
-
2001
- 2001-11-09 US US09/986,792 patent/US6573376B2/en not_active Expired - Lifetime
-
2002
- 2002-09-12 US US10/241,585 patent/US6617452B2/en not_active Expired - Lifetime
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100400043C (zh) * | 2001-04-24 | 2008-07-09 | Hf医药研究有限公司 | 加兰他敏在制备治疗精神物质所致中枢神经系统病症药物中的应用 |
| CN101080231B (zh) * | 2004-12-17 | 2010-11-17 | 因德纳有限公司 | 氢溴酸加兰他敏的制备方法 |
| CN101787028B (zh) * | 2010-01-12 | 2012-01-04 | 恩施清江生物工程有限公司 | 一种从忽地笑中提取加兰他敏的方法 |
| CN102050826A (zh) * | 2010-12-21 | 2011-05-11 | 浙江工业大学 | 一种分离加兰他敏的方法 |
| CN102050826B (zh) * | 2010-12-21 | 2012-11-14 | 浙江工业大学 | 一种分离加兰他敏的方法 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1088460C (zh) | 分离加兰他敏的方法 | |
| CN110151823A (zh) | 一种肉桂精油的应用 | |
| US4769452A (en) | Production of purity benzo-c-phenanthridine alkaloid salts | |
| US3192111A (en) | Method of inducing therapeutic tranquilization with psilocybin and psilocin | |
| CN106397437A (zh) | 石松生物碱类化合物，其药物组合物及其制备方法和用途 | |
| CN100335073C (zh) | 木鳖子含三萜皂甙成分提取物的制备方法 | |
| CN1806831B (zh) | 一种治疗银屑病的药物及其制备方法 | |
| Petrichenko et al. | Chemical composition and antioxidant properties of biologically active compounds from Euphrasia brevipila | |
| DE2028403A1 (de) | Pepstatin | |
| KR20020031288A (ko) | 엽록소 추출 방법 | |
| DE60207257T2 (de) | Heterocarpin, ein protein, das humanes ghrh bindet | |
| CN112250655A (zh) | 两种新的环状二苯基庚烷类化合物及其制备方法和用途 | |
| JP2003500346A (ja) | 皮膚美白剤 | |
| KR100703242B1 (ko) | 식물성 물질로부터 화합물을 추출하는 방법 | |
| EP0248215A2 (de) | Arzneimittel mit dopaminerger Wirkung | |
| KR890000651B1 (ko) | 은행잎으로부터 고농도의 푸라보노이드의 추출방법 | |
| US2407713A (en) | Erythrina alkaloid and its production | |
| Hay | A NEW ALKALOID IN CANNABIS INDICA. | |
| US2391014A (en) | Alkaloidal "free" fraction from species of erythrina and processes for its production | |
| MXPA97007015A (en) | Procedure to isolate galantam | |
| RO119586B1 (ro) | Procedeu de obţinere a extractului uscat stabil din herba corydali |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CX01 | Expiry of patent term |
Granted publication date: 20020731 |
|
| EXPY | Termination of patent right or utility model |